Dialectic Therapeutics is a biotechnology company based in Dallas, Texas, dedicated to developing innovative technologies to treat cancer. Founded by respected cancer scientists and successful biotech investors, the company focuses on creating impactful anti-cancer drugs that effectively target patients with limited treatment options. With research partners and facilities at UT Health at San Antonio and the University of Florida Health Cancer Center, Dialectic Therapeutics is committed to relieving the suffering of cancer patients, providing hope, and prolonging their productive lives through targeted therapies with minimal toxicities and complications.
One of Dialectic's lead candidates, DT2216, is a novel compound that selectively induces cancer cells to degrade B-cell lymphoma extra large (BCL-XL), leading to cell death or increased susceptibility to chemotherapy. This compound has shown high effectiveness in various liquid and solid tumors, both as a single agent and in combination with chemotherapy, with minimal toxicity. Dialectic Therapeutics aims to address the high unmet need in cancer treatment by developing drug candidates that target other significant proteins associated with cancer, using their unique APTaD platform. If successful, these innovative therapies have the potential to provide increased disease-free survival for cancer patients with limited hope.
Generated from the website